◎记者 汪友若 5月7日，中国人民银行、金融监管总局、中国证监会联合推出一揽子金融政策，从货币政策、金融监 管、资本市场建设等多维度发力，贯彻落实中央政治局会议"持续稳定和活跃资本市场"的决策部署。 投行业务中，并购重组市场不断升温，券商在方案设计、交易撮合、融资安排等方面具有专业优势，并 购重组财务顾问业务面临发展机遇。 资管产品方面，盘活存量资产、支持基础设施建设等政策导向，将推动REITs市场和资产证券化业务持 续发展，为券商带来新的业务增长点。 展望未来，徐朝晖认为，政策还有望从四方面发力，进一步巩固和提升市场动能。一是通过政策引导和 市场机制，鼓励上市公司聚焦主业，提升核心竞争力；二是支持上市公司加大研发投入，推动科技创新 和产业升级；三是支持优质企业通过并购重组做优做强，支持上市公司通过市场化方式进行产业整合和 价值提升；四是引导上市公司完善公司治理结构，提高决策透明度和科学性，鼓励上市公司通过现金分 红、股份回购等方式积极回报投资者。 "平衡'稳定'与'活跃'是一个动态的过程，政策既要为市场划出清晰的底线和红线，保障其稳定运行，又 要为市场留出足够的空间和弹性，激发其内在活力。通过多方面、系统性 ...

Core Viewpoint - The demand for orthopedic surgeries is increasing due to aging populations and younger patients with orthopedic diseases, driving the need for precision, minimally invasive, and intelligent surgical solutions, which in turn fosters the growth of orthopedic surgical robots [2][7]. Group 1: Company Overview - Beijing Tianzhihang Medical Technology Co., Ltd. (Tianzhihang) is transforming the global orthopedic surgical robot market with its core product, the Tianji orthopedic surgical robot, achieving sub-millimeter precision and completing over 110,000 surgeries across more than 200 hospitals in China [2][4]. - The company adheres to the principle of "original research and innovation," with R&D investment of 117 million yuan in 2024, accounting for 65.34% of its revenue, and employs 123 R&D personnel, making up 40.07% of its workforce [3][4]. Group 2: Product Development - Tianzhihang has introduced multiple generations of its surgical robots, with the Tianji® 1.0 launched in 2016 and the Tianji® 2.0 in 2021, enhancing usability and humanization [4]. - The company has achieved full coverage in three major orthopedic fields: spine, trauma, and joints, with a total of 596 patent applications, including 232 invention patents, and 401 patents granted [4][8]. Group 3: Technological Advancements - Tianzhihang has pioneered remote orthopedic surgeries in China since 2006 and has conducted over 1,000 remote surgeries using 5G technology, showcasing the potential of "5G + robotics" in healthcare [6][8]. - The company emphasizes the importance of orthopedic surgical robots in addressing uneven distribution of medical resources and enhancing capabilities in grassroots medical institutions [7]. Group 4: Market Position and Growth - The Chinese surgical robot market is projected to reach approximately 9.59 billion yuan in 2024, with a compound annual growth rate of 34.5% over the past five years, and is expected to grow to 11.03 billion yuan by 2025 [8]. - Tianzhihang's revenue structure has evolved, with more than 50% of its income now coming from consumables and technical services, compared to nearly 100% from hardware four years ago [8]. Group 5: International Expansion - The company aims to expand internationally, with its surgical navigation systems receiving EU CE certification, facilitating its entry into overseas markets [9]. - Tianzhihang plans to develop differentiated market strategies based on the characteristics of various international markets, positioning itself as a significant player in the global orthopedic surgical robot arena [9].

本报记者 袁传玺 近日，国际数据公司IDC发布的《中国2024年AI数字人市场份额》报告显示，2024年中国AI数字人市场规模约41.2亿元， 同比增长85.3%，实现高速增长。 国内AI数字人市场的高速增长，离不开技术的进步。在生成式AI与大模型技术浪潮下，2025年，AI数字人正以前所未有的 速度从概念走向规模化应用，成为产业数字化转型进程中的焦点与新引擎。 百度集团股份有限公司（以下简称"百度"）副总裁、电商总经理平晓黎表示，今年4月份百度发布的高说服力数字人已让 数字人进入3.0时代，标志着智能电商迈入新篇章，新一代高说服力数字人成为了一个"形神音容"高度协调、会思考决策、能协 作完成特定任务的超级智能体。 AI数字人加速普及 以百度高说服力数字人为例，百度研制的多模协同的数字人技术，基于文心4.5T实现了融合多模规划与深度思考的剧本生 成，由剧本驱动数字人多模协同，实现动态决策的实时交互，使数字人的"神、形、音、容、话"达到高度统一，最终呈现出一 个具备高表现力、内容吸引人、"人—物—场"可自由交互的超拟真数字人。 平晓黎表示，百度的罗永浩数字人已达到媲美头部主播的体感效果，随着大模型与多模能力发展 ...

Core Viewpoint - Fengcai Technology (Shenzhen) Co., Ltd. is in the process of issuing H shares and listing on the Hong Kong Stock Exchange, with the necessary application materials published on the exchange's website [1][2]. Group 1 - The company has received confirmation from the China Securities Regulatory Commission regarding the filing for the overseas issuance and listing of H shares [2]. - The purpose of publishing the post-hearing information package is solely to provide information to the public and qualified investors in Hong Kong, and it is a draft version subject to updates [2][3]. - The company will not publish the post-hearing information package on domestic stock exchanges or media, but provides links for domestic investors to access the information [3]. Group 2 - The issuance and listing are still subject to final approval from relevant regulatory bodies, including the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, indicating uncertainty in the process [4].

| 目 | 录 | .2024 | ………………………………… | (1 | ) | 年度董事会工作报告 | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | .2024 | ………………………………… | ( | 年度监事会工作报告 | .2024 | 年度独立董事述职报告 | | | | | | | | | | | | | | | | | | | | | | ( | ( | | | | | | | | | | | | | | | | | | | | | | | | | | ( | ( | 54) | | | | | | | | | | | | | | | | | | | | | | | | | .2024 | …………………………………………… | ( | 年年度报 ...

来源|贝多财经 近日，峰岹科技（深圳）股份有限公司（下称"峰岹科技"，SH:688279）通过港交所上市聆讯，并披露了聆讯后资料集（招股书）。据贝多财经了解，峰岹 科技是一家A股上市公司，于2025年1月在港交所递表。 公开信息显示，峰岹科技于2022年4月20日在上海证券交易所科创板上市，IPO发行价为82.00元/股。但在上市首日，峰岹科技就跌破发行价，开盘报61.00 元/股，最高71.80元/股，最低60.00元/股，收报66.20元/股，跌幅19.27%，市值约61亿元。 几经波动，峰岹科技的股价于2025年3月6日一度突破314.16元/股，创历史新高，市值约为290亿元。而截至2025年6月20日，峰岹科技的股价报收194.46元/ 股，市值约为180亿元，较历史最高值缩减约110亿元。 与之对应的是，峰岹科技于2025年1月10日召开2025年第一次临时股东大会，审议通过了《关于公司发行H股股票并在香港联合交易所有限公司上市的议 案》《关于公司发行H股募集资金使用计划的议案》等。 据招股书介绍，峰岹科技是一家芯片设计公司，专注于BLDC电机驱动控制芯片的设计与研发。其中，BLDC电机是一种采用 ...

■本报记者 李美丽 近期，山东省聊城市冠县东古城镇田马园村的樱桃喜获丰收，道路两旁随处可见由樱桃堆砌成的小山 丘，吸引了众多客商前来采购。 "今年村民心里十分踏实，因为樱桃不仅生长得旺盛，而且大家加入了'樱桃保险'，这让我们心里有保 障。"田马园村党支部书记田英冲介绍，全村有超3000亩樱桃投保了中国人寿财险聊城市中心支公司推 出的"樱桃（树）种植保险"。 近年来，中国人寿财险聊城市中心支公司针对冠县樱桃产业，构建了樱桃全生命周期保险体系，实现了 保险从"灾后补偿"工具向"产业稳定器"的转变，为特色农业产业的健康发展提供了保障。 财金联动"兜底" 树果共保化风险 早在20世纪90年代，田马园村开始规模化种植樱桃，带动冠县全县樱桃种植面积迅速增长，目前已超过 3万亩，成为全国最大的早熟大樱桃栽培基地。然而，2020年至2023年，风灾、倒春寒、根腐病等多种 灾害对冠县樱桃产业造成冲击，导致樱桃种植户连年遭受损失。 在此背景下，2023年，冠县财政局、林业局、金融监管和运行监测等部门与中国人寿财险聊城市中心支 公司合作，为当地樱桃产业定制了财政补贴性樱桃种植保险。2024年，在"保果"基础上，该保险产品新 增了" ...

Core Insights - Jincheng Pharmaceutical has experienced significant growth since its listing in June 2011, with its market capitalization increasing from 2.465 billion yuan to 5.862 billion yuan, reflecting a deep focus on the pharmaceutical intermediate sector [1][6] - The company's main business includes the research, production, and sales of cephalosporin antibiotic intermediates, with the highest revenue contribution coming from formulation products at 35.30% [3] - Over the 14 years since its IPO, Jincheng Pharmaceutical has achieved a cumulative profit growth of 251.45%, with net profit reaching 197 million yuan in the latest fiscal year [3][4] Financial Performance - Revenue has shown stable growth, increasing from 2.962 billion yuan in 2020 to 3.373 billion yuan in 2024 [4] - The company has recovered from a loss of 489 million yuan in 2020 to a net profit of 197 million yuan in 2024, indicating a significant turnaround in profitability [4] - The company's net profit has fluctuated, with 7 out of 14 years showing profit growth, highlighting a volatile earnings trend [3] Market Capitalization - Since its IPO, Jincheng Pharmaceutical's market value has increased by 138%, peaking at 17.555 billion yuan in July 2021 [6] - As of June 20, the company's market capitalization was 5.862 billion yuan, down 11.693 billion yuan from its peak, representing a 66.61% decrease [6]

Group 1 - The article highlights the integration of meteorological technology with financial services to enhance the profitability of local agricultural products in Shandong Province, particularly in Shizhu County [1] - The establishment of a smart mushroom greenhouse equipped with IoT monitoring systems has enabled farmers to cultivate mushrooms more scientifically, improving yield and quality [2][3] - The local mushroom cooperative received a loan of 1.4 million yuan from Postal Savings Bank, resulting in an annual output value of 4.8 million yuan and a 20% increase in yield due to advanced monitoring and management techniques [3] Group 2 - The article discusses the development of a climate-friendly agricultural industry in Shizhu County, with a focus on creating high-value products through climate brand certification and the introduction of various processed products [4] - Postal Savings Bank has tailored financial services to meet the specific needs of local climate-friendly enterprises, offering specialized loan products such as "Mushroom Loan," "Walnut Loan," and "Tea Loan" to support rural revitalization [4] - As of May, Postal Savings Bank has provided over 80 million yuan in loans to climate-friendly enterprises in Shizhu County, covering various sectors and addressing financing challenges for local businesses [5]

Group 1 - The pricing discrepancy between A-shares and H-shares of Sanhua Intelligent Control is significant, with H-shares priced at HKD 21.21 to 22.53, representing a 30% discount compared to the A-share price of RMB 25.26 [2][3] - The A-share dynamic price-to-earnings ratio is 27 times, while the H-share issuance is at approximately 20 times, indicating a dilution effect on A-share holders' rights due to the secondary listing [3] - The company's stock price has dropped 32% from a peak of RMB 36.62 on February 28, 2025, to RMB 24.95 on June 20, 2025, despite significant investment from cornerstone investors [5] Group 2 - Sanhua Intelligent Control's revenue from its largest customer, a major American automotive company (widely recognized as Tesla), has seen a 22% decline, with Tesla's global deliveries dropping 13% in the first quarter of 2025 [6] - The company faces increased tariffs on exports to the U.S., with rates soaring from a maximum of 29% to 99%, and similar increases for exports to Mexico and Vietnam, raising concerns about cost management [6][7] - The anticipated growth from the robotics segment is still in the research and development phase, with profitability expected to take years, while the core appliance and automotive segments are under pressure from declining sales and external tariffs [8]